2 results
Approved WMOPending
The primary objective of this study is to estimate the incidence of ocular adverse events in patients with CNV secondary to AMD who receive an individualized treatment with ranibizumab 0,3 mg.
Approved WMOCompleted
38819: To investigate the efficacy and safety of a single injection of Org 36286 to induce multifollicular development for COS using daily recFSH as a reference.38821: To evaluate whether Org 36286 treatment for the induction of multifollicular…